Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Seymour, JF"" wg kryterium: Autor


Tytuł:
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care.
Autorzy:
Anderson MA; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.; Division of Blood Cells and Blood Cancers, The Walter and Eliza Hall Institute, Melbourne, VIC 3000, Australia.; Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC 3000, Australia.
Walewska R; University Hospitals Dorset, NHS Foundation Trust, Bournemouth BH7 7DW, UK.
Hackett F; Cancer Services Directorate, University Hospital Limerick UL Hospitals Group, St. Nessan's Road, V94 F858 Limerick, Ireland.
Kater AP; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands.
Montegaard J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
O'Brien S; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA.
Seymour JF; Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC 3000, Australia.
Smith M; Department of Haematology, Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield S44 5BL, UK.
Stilgenbauer S; Division of CLL, Department of Internal Medicine III, Ulm University, 89081 Ulm, Germany.
Whitechurch A; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.
Brown JR; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2024 Feb 28; Vol. 16 (5). Date of Electronic Publication: 2024 Feb 28.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Tytuł:
Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.
Autorzy:
Hall VG; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Australia.
Nguyen THO; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Australia.
Allen LF; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Australia.
Rowntree LC; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Australia.
Kedzierski L; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Australia.
Chua BY; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Australia.; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, Hokkaido, Japan.
Lim C; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
Saunders NR; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
Klimevski E; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
Tennakoon GS; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
Seymour JF; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Wadhwa V; Department of Ambulatory Services, Peter MacCallum Cancer Centre, Melbourne, Australia.
Cain N; Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Vo KL; Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Nicholson S; Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Karapanagiotidis T; Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Williamson DA; Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Thursky KA; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Spelman T; Department of Biostatistics and Epidemiology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Centre for Population Health, Burnet Institute, Melbourne, Australia.
Yong MK; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Slavin MA; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Kedzierska K; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Australia.; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, Hokkaido, Japan.
Teh BW; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Pokaż więcej
Źródło:
Open forum infectious diseases [Open Forum Infect Dis] 2023 Nov 02; Vol. 10 (11), pp. ofad550. Date of Electronic Publication: 2023 Nov 02 (Print Publication: 2023).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
Autorzy:
Bennett R; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne, VIC, 3000, Australia.
Anderson MA; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne, VIC, 3000, Australia.; Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, 1G, Royal Parade, Parkville, Melbourne, VIC, 3052, Australia.; University of Melbourne, Grattan St, Parkville, Melbourne, VIC, 3010, Australia.
Seymour JF; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne, VIC, 3000, Australia. John.seymour@petermac.org.; University of Melbourne, Grattan St, Parkville, Melbourne, VIC, 3010, Australia. John.seymour@petermac.org.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 Jul 08; Vol. 16 (1), pp. 72. Date of Electronic Publication: 2023 Jul 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzamides/therapeutic use ; Agammaglobulinaemia Tyrosine Kinase
Czasopismo naukowe
Tytuł:
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
Autorzy:
Wierda WG; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kipps TJ; UCSD Moores Cancer Center, San Diego, CA, USA.
Al-Sawaf O; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Düsseldorf, German CLL Study Group, University Hospital, University of Cologne, Cologne, Germany.
Chyla B; AbbVie Inc., North Chicago, IL, USA.
Biondo JML; Genentech, Inc., South San Francisco, CA, USA.
Mun Y; Genentech, Inc., South San Francisco, CA, USA.
Jiang Y; Genentech, Inc., South San Francisco, CA, USA.
Seymour JF; Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne, Melbourne, VIC, Australia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2765-2784. Date of Electronic Publication: 2022 Aug 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Neoplasm, Residual/drug therapy ; Treatment Outcome ; Proto-Oncogene Proteins c-bcl-2/genetics
Czasopismo naukowe
Tytuł:
Development of a distributed international patient data registry for hairy cell leukemia.
Autorzy:
Andritsos LA; Division of Hematology Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
Anghelina M; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Neal J; Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Blachly JS; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Mathur P; Department of Research Information Technology, College of Medicine, The Ohio State University, Columbus, OH, USA.
Lele O; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Dearden C; The Royal Marsden NHS Foundation Trust, London, UK.
Iyengar S; The Royal Marsden NHS Foundation Trust, London, UK.
Cross M; The Royal Marsden NHS Foundation Trust, London, UK.
Zent CS; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Rogers KA; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Epperla N; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Lozanski G; Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA.
Oakes CC; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Kraut E; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Ruppert AS; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Zhao Q; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Bhat SA; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Forconi F; Cancer Sciences and Haematology Department, University of Southampton Hospital Trust, Southampton, UK.
Banerji V; Department of Internal Medicine & Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.; Research Institute in Oncology and Hematology, Winnipeg, Canada.
Handunnetti S; Haematology Department, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
Tam CS; Haematology Department, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
Seymour JF; Haematology Department, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
Else M; The Institute of Cancer Research, London, UK.
Kreitman RJ; Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA.
Saven A; Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA.
Call T; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Parikh SA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Johnston JB; Department of Internal Medicine & Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.; Research Institute in Oncology and Hematology, Winnipeg, Canada.
Tiacci E; Department of Medicine and Surgery, Institute of Hematology, University and Hospital of Perugia, Perugia, Italy.
Troussard X; Department of Hematology, Centre Hospitalier Universitaire Cote de Nacre, Caen, France.
Tallman MS; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dietrich S; Department of Hematology, University Hospital of Heidelberg, Heidelberg, Germany.
Tadmor T; Hematology Division, Bnai Zion Medical Center and The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Gozzetti A; Department of Medicine, University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
Zinzani PL; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, IRCCS Azienda Ospedaliero-Universitaria di Bologna and Istituto di Ematologia 'Seràgnoli', Bologna, Italy.
Robak T; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Quest G; Pathology and Molecular Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, Canada.
Demeter J; Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Rai K; Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA.
Fernandez SA; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Grever M; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (13), pp. 3021-3031. Date of Electronic Publication: 2022 Sep 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Leukemia, Hairy Cell*/diagnosis
Leukemia, Hairy Cell*/epidemiology
Leukemia, Hairy Cell*/therapy
Humans ; Treatment Outcome ; Registries
Czasopismo naukowe
Tytuł:
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.
Autorzy:
Lew TE; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.; Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Seymour JF; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia. john.seymour@petermac.org.; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia. john.seymour@petermac.org.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2022 Jun 03; Vol. 15 (1), pp. 75. Date of Electronic Publication: 2022 Jun 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*
Lymphoma, B-Cell*/drug therapy
Multiple Myeloma*/drug therapy
Adult ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Humans ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use
Czasopismo naukowe
Tytuł:
Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia.
Autorzy:
Odutola MK; Centre for Big Data Research in Health, University of New South Wales, Sydney 2052, Australia.
van Leeuwen MT; Centre for Big Data Research in Health, University of New South Wales, Sydney 2052, Australia.
Turner J; Department of Anatomical Pathology, Douglass Hanly Moir Pathology, Macquarie Park 2113, Australia.; Department of Clinical Medicine, Faculty of Medicine, Health and Human Science, Macquarie University, North Ryde 2109, Australia.
Bruinsma F; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne 3004, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville 3010, Australia.
Seymour JF; Royal Melbourne Hospital, Melbourne 3052, Australia.; Peter MacCallum Cancer Centre, University of Melbourne, Parkville 3010, Australia.
Prince HM; Peter MacCallum Cancer Centre, University of Melbourne, Parkville 3010, Australia.; Epworth Healthcare, Richmond 3121, Australia.
Milliken ST; St. Vincent's Hospital, Sydney 2010, Australia.; University of New South Wales, Sydney 2052, Australia.
Trotman J; Concord Repatriation General Hospital, Concord 2139, Australia.; Faculty of Medicine and Health, University of Sydney, Concord 2139, Australia.
Verner E; Concord Repatriation General Hospital, Concord 2139, Australia.; Faculty of Medicine and Health, University of Sydney, Concord 2139, Australia.
Tiley C; Gosford Hospital, Gosford 2250, Australia.; School of Medicine and Public Health, The University of Newcastle, Newcastle 2308, Australia.
Roncolato F; University of New South Wales, Sydney 2052, Australia.; St. George Hospital, Kogarah 2217, Australia.
Underhill CR; Rural Medical School, Albury 2640, Australia.; Border Medical Oncology Research Unit, Albury 2640, Australia.
Opat SS; Clinical Haematology, Monash Health and Monash University, Clayton 3168, Australia.
Harvey M; Liverpool Hospital, Liverpool 2170, Australia.; Western Sydney University, Sydney 2000, Australia.
Hertzberg M; University of New South Wales, Sydney 2052, Australia.; Department of Haematology, Prince of Wales Hospital, Sydney 2031, Australia.
Benke G; School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia.
Giles GG; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne 3004, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville 3010, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton 3168, Australia.
Vajdic CM; Centre for Big Data Research in Health, University of New South Wales, Sydney 2052, Australia.; Kirby Institute, University of New South Wales, Sydney 2052, Australia.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 May 30; Vol. 14 (11). Date of Electronic Publication: 2022 May 30.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas.
Autorzy:
Minson A; Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
Tam C; Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
Dickinson M; Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
Seymour JF; Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Mar 01; Vol. 14 (5). Date of Electronic Publication: 2022 Mar 01.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Tytuł:
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
Autorzy:
McQuilten ZK; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.; Department of Haematology, Monash Health, Melbourne, Australia.
Busija L; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Stanworth S; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Clinical Department, NHS Blood and Transplant, Oxford, UK.; Radcliffe Department of Medicine, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, UK.
Wood EM; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.; Department of Haematology, Monash Health, Melbourne, Australia.
Kenealy M; Cabrini Health, Melbourne, Australia.; Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia.
Weinkove R; Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealand.; Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.; Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
Pokaż więcej
Corporate Authors:
Australasian Leukaemia and Lymphoma Group (ALLG)
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Mar; Vol. 63 (3), pp. 676-683. Date of Electronic Publication: 2021 Dec 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Myelodysplastic Syndromes*/diagnosis
Myelodysplastic Syndromes*/drug therapy
Aged ; Antimetabolites, Antineoplastic/adverse effects ; Azacitidine/adverse effects ; Dyspnea/drug therapy ; Dyspnea/etiology ; Fatigue/etiology ; Hemoglobins ; Humans ; Quality of Life
Czasopismo naukowe
Tytuł:
Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy.
Autorzy:
Shanavas M; Mater Research University of Queensland Brisbane QLD Australia.; Department of Haematology Mater Hospital Brisbane QLD Australia.
Law SC; Mater Research University of Queensland Brisbane QLD Australia.
Hertzberg M; Department of Haematology Prince of Wales Hospital and University of NSW Randwick NSW Australia.
Hicks RJ; Department of Cancer Imaging Peter MacCallum Cancer Centre East Melbourne Melbourne VIC Australia.
Seymour JF; Department of Haematology Peter MacCallum Cancer Centre Royal Melbourne Hospital & University of Melbourne Parkville VIC Australia.
Li Z; Centre for Genomics and Personalised Health School of Biomedical Sciences, Faculty of Health Translational Research Institute Queensland University of Technology (QUT) Woolloongabba QLD Australia.
Merida de Long L; Mater Research University of Queensland Brisbane QLD Australia.
Nath K; Mater Research University of Queensland Brisbane QLD Australia.
Sabdia MB; Mater Research University of Queensland Brisbane QLD Australia.
Gunawardana J; Mater Research University of Queensland Brisbane QLD Australia.
Gandhi MK; Mater Research University of Queensland Brisbane QLD Australia.; Department of Haematology Princess Alexandra Hospital Brisbane QLD Australia.
Keane C; Mater Research University of Queensland Brisbane QLD Australia.; Department of Haematology Princess Alexandra Hospital Brisbane QLD Australia.
Pokaż więcej
Źródło:
Clinical & translational immunology [Clin Transl Immunology] 2021 Oct 27; Vol. 10 (11), pp. e1351. Date of Electronic Publication: 2021 Oct 27 (Print Publication: 2021).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL.
Autorzy:
Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne, Melbourne, Australia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Oct; Vol. 62 (10), pp. 2299-2302. Date of Electronic Publication: 2021 Sep 29.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Rituximab/therapeutic use
Czasopismo naukowe
Tytuł:
Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?
Autorzy:
Anderson MA; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.; Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, Parkville, Australia.
Seymour JF; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Medicine Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Oct; Vol. 61 (10), pp. 2286-2288. Date of Electronic Publication: 2020 Aug 04.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Tumor Lysis Syndrome*/diagnosis
Tumor Lysis Syndrome*/epidemiology
Tumor Lysis Syndrome*/etiology
Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Humans ; Incidence ; Patients ; Sulfonamides
Czasopismo naukowe
Tytuł:
The evolving definition of bulky disease for lymphoma.
Autorzy:
Buteau JP; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Hofman MS; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jul; Vol. 61 (7), pp. 1525-1528. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Fluorodeoxyglucose F18*
Lymphoma, Large B-Cell, Diffuse*
Humans ; Positron Emission Tomography Computed Tomography ; Prognosis
Czasopismo naukowe
Tytuł:
The urgent need for integrated science to fight COVID-19 pandemic and beyond.
Autorzy:
Moradian N; Universal Scientific Education and Research Network (USERN),.; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, 14194, Iran.
Ochs HD; Universal Scientific Education and Research Network (USERN),.; Department of Pediatrics, University of Washington and Seattle Children's Research Institute, Seattle, WA, USA.
Sedikies C; Universal Scientific Education and Research Network (USERN),.; Centre for Research on Self Identity, Department of Psychology, School of Psychology, University of Southampton, Southampton, UK.
Hamblin MR; Universal Scientific Education and Research Network (USERN),.; Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA.; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, 2028, South Africa.
Camargo CA Jr; Universal Scientific Education and Research Network (USERN),.; Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Martinez JA; Universal Scientific Education and Research Network (USERN),.; University of Navarra, CIBERobn and IMDEA food, International Union of Nutritional Sciences (IUNS), Navarra, Spain.; International Union of Nutritional Sciences (IUNS), London, UK.
Biamonte JD; Universal Scientific Education and Research Network (USERN),.; Skolkovo Institute of Science and Technology, Moscow, Russia.
Abdollahi M; Universal Scientific Education and Research Network (USERN),.; Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Torres PJ; Universal Scientific Education and Research Network (USERN),.; Departamento de Matemática Aplicada, Universidad de Granada, 18071, Granada, Spain.
Nieto JJ; Universal Scientific Education and Research Network (USERN),.; Instituto de Matemáticas, Universidade de Santiago de Compostela, Santiago De Compostela, Spain.
Ogino S; Universal Scientific Education and Research Network (USERN),.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Seymour JF; Universal Scientific Education and Research Network (USERN),.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Abraham A; Universal Scientific Education and Research Network (USERN),.; Machine Intelligence Research Labs, Auburn, WA, USA.
Cauda V; Universal Scientific Education and Research Network (USERN),.; Department of Applied Science and Technology, Politecnico di Torino Corso, Duca degli Abruzzi 24, 10129, Turin, Italy.
Gupta S; Universal Scientific Education and Research Network (USERN),.; Division of Basic and Clinical Immunology, University of California Irvine, California, USA.
Ramakrishna S; Universal Scientific Education and Research Network (USERN),.; National University of Singapore, Singapore, Singapore.
Sellke FW; Universal Scientific Education and Research Network (USERN),.; Division of Cardiothoracic Surgery, Department of Surgery, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, 02903, USA.
Sorooshian A; Universal Scientific Education and Research Network (USERN),.; Department of Chemical and Environmental Engineering, University of Arizona, Tucson, AZ, USA.; Department of Hydrology and Atmospheric Sciences, University of Arizona, Tucson, AZ, USA.
Wallace Hayes A; Universal Scientific Education and Research Network (USERN),.; A. Wallace Hayes, University of South, Florida College of Public Health and Institute for Integrative Toxicology, Michigan State University, East Lansing, USA.
Martinez-Urbistondo M; Internal Medicine and Infections Service, Hospital Puerta De Hierro, Madrid, Spain.
Gupta M; Universal Scientific Education and Research Network (USERN),.; Department of Mechanical Engineering, National University of Singapore, Singapore, Singapore.
Azadbakht L; Universal Scientific Education and Research Network (USERN),.; Department of Mechanical Engineering, National University of Singapore, Singapore, Singapore.
Esmaillzadeh A; Universal Scientific Education and Research Network (USERN),.; Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Kelishadi R; Universal Scientific Education and Research Network (USERN),.; Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
Esteghamati A; Universal Scientific Education and Research Network (USERN),.; Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Tehran, Iran.
Emam-Djomeh Z; Universal Scientific Education and Research Network (USERN),.; Department of Food Science, Engineering and Technology, College of Agriculture & Natural Resources, University of Tehran, Karaj Campus, Karaj, Iran; Transfer Phenomena Laboratory (TPL), Controlled Release Center, University of Tehran, Karaj Campus, Karaj, Iran.
Majdzadeh R; Universal Scientific Education and Research Network (USERN),.; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Palit P; Universal Scientific Education and Research Network (USERN),.; Department of Pharmaceutical Sciences, Drug Discovery Research Laboratorty, Assam University, Silchar, Assam, India.
Badali H; Universal Scientific Education and Research Network (USERN),.; Invasive Fungi Research Center and Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.; Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, USA.
Rao I; Universal Scientific Education and Research Network (USERN),.; Centro Internacional de Agricultura Tropical (CIAT), Cali, Colombia.
Saboury AA; Universal Scientific Education and Research Network (USERN),.; Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Jagan Mohan Rao L; Universal Scientific Education and Research Network (USERN),.; Spice and Flavour Science Department, CSIR-Central Food Technological Research Institute, Mysore, India.
Ahmadieh H; Universal Scientific Education and Research Network (USERN),.; Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Montazeri A; Universal Scientific Education and Research Network (USERN),.; Population Health Research Group, Health Metrics Research Center, Institute for Health Sciences Research, ACECR, Tehran, Iran.
Fadini GP; Universal Scientific Education and Research Network (USERN),.; Department of Medicine, Division of Metabolic Diseases and, Padova Hospital, University of Padova, Padua, Italy.
Pauly D; Universal Scientific Education and Research Network (USERN),.; Institute for the Oceans and Fisheries, University of British Columbia, Vancouver, BC, Canada.
Thomas S; Universal Scientific Education and Research Network (USERN),.; School of Chemical Sciences, Mahatma Gandhi University, Kerala, 686 560, India.
Moosavi-Movahed AA; Universal Scientific Education and Research Network (USERN),.; Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Aghamohammadi A; Universal Scientific Education and Research Network (USERN),.; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, 14194, Iran.
Behmanesh M; Universal Scientific Education and Research Network (USERN),.; Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Rahimi-Movaghar V; Universal Scientific Education and Research Network (USERN),.; Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Ghavami S; Universal Scientific Education and Research Network (USERN),.; Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3E 3P4, Canada.; Faculty of Medicine, Katowice School of Technology, 40-555, Katowice, Poland.
Mehran R; Universal Scientific Education and Research Network (USERN),.; Zena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at Mount Sinai and Cardiovascular Research Foundation, New York, NY, USA.
Uddin LQ; Universal Scientific Education and Research Network (USERN),.; Department of Psychology, University of Miami, Miami, USA.
Von Herrath M; Universal Scientific Education and Research Network (USERN),.; Center for Type 1, Diabetes Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Mobasher B; Universal Scientific Education and Research Network (USERN),.; Department of Physics and Astronomy, University of California Riverside, Riverside, CA, 92521, USA.
Rezaei N; Universal Scientific Education and Research Network (USERN), , . rezaei_.; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, 14194, Iran. rezaei_.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2020 May 19; Vol. 18 (1), pp. 205. Date of Electronic Publication: 2020 May 19.
Typ publikacji:
Historical Article; Journal Article; Review
MeSH Terms:
Emergencies*
Health Services Needs and Demand*
Pandemics*
Biomedical Research/*organization & administration
Coronavirus Infections/*epidemiology
Delivery of Health Care, Integrated/*organization & administration
Pneumonia, Viral/*epidemiology
Betacoronavirus/pathogenicity ; Biomedical Research/methods ; COVID-19 ; Coronavirus Infections/therapy ; Coronavirus Infections/virology ; Delivery of Health Care, Integrated/methods ; History, 21st Century ; Humans ; Interdisciplinary Communication ; Interdisciplinary Studies ; Pneumonia, Viral/therapy ; Pneumonia, Viral/virology ; Public Health/history ; Public Health/standards ; SARS-CoV-2
Czasopismo naukowe
Tytuł:
Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy.
Autorzy:
MacManus MP; Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
Hicks RJ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.; Department of Molecular Imaging, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.
Bressel M; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.
Campbell BA; Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
Wirth A; Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
Ryan G; Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
Prince HM; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne VIC 3000, Australia.
Wolf M; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne VIC 3000, Australia.
Brown R; Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.
Seymour JF; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne VIC 3000, Australia.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 Apr 17; Vol. 12 (4). Date of Electronic Publication: 2020 Apr 17.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Autorzy:
Deng R; Genentech Inc, South San Francisco, CA, USA.
Gibiansky L; QuantPharm, LLC, North Potomac, MD, USA.
Lu T; Genentech Inc, South San Francisco, CA, USA.
Li X; Genentech Inc, South San Francisco, CA, USA.
Lu D; Genentech Inc, South San Francisco, CA, USA.
Li C; Genentech Inc, South San Francisco, CA, USA.
Girish S; Genentech Inc, South San Francisco, CA, USA.
Wang J; Genentech Inc, South San Francisco, CA, USA.
Boyer M; F. Hoffmann - La Roche Ltd, Welwyn Garden City, UK.
Shankar N; Genentech Inc, South San Francisco, CA, USA.
Humphrey K; F. Hoffmann - La Roche Ltd, Welwyn Garden City, UK.
Freise KJ; AbbVie, North Chicago, IL, USA.
Salem AH; AbbVie, North Chicago, IL, USA.; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Seymour JF; Royal Melbourne Hospital, Peter MacCallum Cancer Centre, & University of Melbourne, Melbourne, Australia.
Kater AP; Department of Hematology, Cancer Center Amsterdam, Hovon CLL Study Group, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Miles D; Genentech Inc, South San Francisco, CA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jan; Vol. 61 (1), pp. 56-65. Date of Electronic Publication: 2019 Sep 24.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Rituximab/therapeutic use ; Sulfonamides
Czasopismo naukowe
Tytuł:
High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.
Autorzy:
Meher-Homji Z; Department of Infectious Diseases, Austin Health, Heidelberg, Australia.
Tam CS; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Haematology, St Vincents Hospital, Melbourne, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia.
Siderov J; Department of Pharmacy, Austin Health, Heidelberg, Australia.
Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia.; Department of Haematology, Royal Melbourne Hospital, Melbourne, Australia.
Holmes NE; Department of Infectious Diseases, Austin Health, Heidelberg, Australia.
Chua KYL; Department of Infectious Diseases, Austin Health, Heidelberg, Australia.
Phillips EJ; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Slavin MA; Department of Medicine, University of Melbourne, Melbourne, Australia.; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
Trubiano JA; Department of Infectious Diseases, Austin Health, Heidelberg, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia.; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (14), pp. 3455-3460. Date of Electronic Publication: 2019 Jul 01.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-Bacterial Agents/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Drug Hypersensitivity/*epidemiology
Leukemia, Hairy Cell/*drug therapy
Adult ; Aged ; Australia/epidemiology ; Case-Control Studies ; Cladribine/administration & dosage ; Drug Hypersensitivity/etiology ; Female ; Follow-Up Studies ; Humans ; Leukemia, Hairy Cell/immunology ; Leukemia, Hairy Cell/pathology ; Male ; Middle Aged ; Prevalence ; Prognosis ; Retrospective Studies ; Survival Rate ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives
Czasopismo naukowe
Tytuł:
A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies.
Autorzy:
Chait-Rubinek L; School of Medicine, University of Notre Dame, Sydney 2010, Australia.
Mariani JA; Department of Cardiovascular Medicine, Alfred Hospital, Melbourne, Australia.; Central Clinical School, Faculty of Medicine, Monash University, Clayton 3168, Australia.; Heart Failure Research Group, Baker Heart and Diabetes Research Institute, Prahran 3181, Australia.
Goroncy N; Department of Nursing, Peter MacCallum Cancer Centre, Melbourne, Australia.
Herschtal A; Centre for Biostatics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia.
Wheeler GC; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Clinical Pathology, University of Melbourne, Parkville, Victoria 3000, Australia.
Dwyer MK; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Clinical Pathology, University of Melbourne, Parkville, Victoria 3000, Australia.
Seymour JF; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3000, Australia.
Campbell BA; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. .; Department of Clinical Pathology, University of Melbourne, Parkville, Victoria 3000, Australia. .
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2019 Jul 24; Vol. 11 (8). Date of Electronic Publication: 2019 Jul 24.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment.
Autorzy:
Wong Doo N; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia. .; Concord Repatriation General Hospital, Sydney Medical School, University of Sydney, Sydney, NSW 2139, Australia. .; Concord Clinical School, University of Sydney, Concord, NSW 2139, Australia. .
White VM; School of Psychology, Faculty of Health, Deakin University, Geelong, Victoria 3220, Australia.; Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.
Martin K; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.
Bassett JK; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.
Prince HM; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia.
Harrison SJ; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia.
Jefford M; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.
Winship I; Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia.; Department of Medicine, The University of Melbourne, Parkville, Victoria 3010, Australia.
Millar JL; Alfred Health Radiation Oncology, Alfred and LaTrobe Regional Hospital, Melbourne, Victoria 3004, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia.
Milne RL; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria 3010, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3800, Australia.
Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia.
Giles GG; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria 3010, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3800, Australia.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2019 Jul 02; Vol. 11 (7). Date of Electronic Publication: 2019 Jul 02.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials.
Autorzy:
Russell L; School of Nursing and Midwifery, Faculty of Health, Deakin University, Geelong, VIC, Australia.
Pascoe MC; Institute of Sport, Exercise and Active Living, Victoria University, Footscray, VIC, Australia.
Seymour JF; Peter MacCallum Cancer Centre, Parkville, Melbourne, VIC, Australia.; Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.
Aranda S; University of Melbourne, Melbourne, VIC, Australia.; Cancer Council Australia, Sydney, Australia.
Butow P; Department of Psychology, University of Sydney, Sydney, Australia.
Gough K; Peter MacCallum Cancer Centre, Parkville, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.
Schofield P; Peter MacCallum Cancer Centre, Parkville, Melbourne, VIC, Australia. .; University of Melbourne, Melbourne, VIC, Australia. .; Swinburne University of Technology, Hawthorn, VIC, Australia. .
Pokaż więcej
Źródło:
BMC research notes [BMC Res Notes] 2019 Apr 15; Vol. 12 (1), pp. 226. Date of Electronic Publication: 2019 Apr 15.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Early Termination of Clinical Trials*
Antineoplastic Agents/*therapeutic use
Medication Adherence/*statistics & numerical data
Mouth Neoplasms/*drug therapy
Telemedicine/*organization & administration
Australia ; Humans ; Mouth Neoplasms/pathology ; Mouth Neoplasms/psychology ; Patient Selection ; Pilot Projects ; Text Messaging
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies